COMMON STOCK PURCHASE WARRANT LEXARIA BIOSCIENCE CORP.Common Stock Purchase Warrant • October 16th, 2024 • Lexaria Bioscience Corp. • Pharmaceutical preparations • New York
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Stockholder Approval Date (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on the date that is the five (5) year anniversary of the Initial Exercise Date, provided that, if such date is not a Trading Day, the date that is the immediately following Trading Day (the “Termination Date”) but not thereafter, to subscribe for and purchase from Lexaria Bioscience Corp., a Nevada corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • April 28th, 2023 • Lexaria Bioscience Corp. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of April __, 2023, between Lexaria Bioscience Corp., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • May 8th, 2020 • Lexaria Bioscience Corp. • Metal mining
This Registration Rights Agreement (this “Agreement”) is made and entered into as of May __, 2020, between Lexaria Bioscience Corp., a Nevada corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”).
PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT LEXARIA BIOSCIENCE CORP.Security Agreement • October 16th, 2024 • Lexaria Bioscience Corp. • Pharmaceutical preparations • New York
THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Stockholder Approval Date (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on October 14, 2029 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Lexaria Bioscience Corp., a Nevada corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant is issued pursuant to that certain engagement letter, dated as of September 4, 2024, by and between the Company and H.C. Wainwright & Co., LLC.
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • October 3rd, 2023 • Lexaria Bioscience Corp. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of September 28, 2023, between Lexaria Bioscience Corp., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
PRE-FUNDED COMMON STOCK PURCHASE WARRANT LEXARIA BIOSCIENCE CORP.Pre-Funded Common Stock Purchase Warrant • October 3rd, 2023 • Lexaria Bioscience Corp. • Pharmaceutical preparations
THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) until this Warrant is exercised in full (the “Termination Date”) but not thereafter, to subscribe for and purchase from Lexaria Bioscience Corp., a Nevada corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
COMMON STOCK PURCHASE WARRANT LEXARIA BIOSCIENCE CORP.Securities Agreement • May 8th, 2020 • Lexaria Bioscience Corp. • Metal mining
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on May __, 2025 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Lexaria Bioscience Corp., a Nevada corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
LEXARIA BIOSCIENCE CORP. and COMPUTERSHARE INC. and COMPUTERSHARE TRUST COMPANY, N.A., as Warrant Agent Warrant Agency Agreement Dated as of April __, 2023Warrant Agency Agreement • April 28th, 2023 • Lexaria Bioscience Corp. • Pharmaceutical preparations • New York
WARRANT AGENCY AGREEMENT, dated as of April __, 2023 (“Agreement”), between Lexaria Bioscience Corp., a corporation organized under the laws of the State of Nevada (the “Company”), and Computershare Inc., a Delaware corporation (“Computershare”), and its affiliate, Computershare Trust Company, N.A., a federally chartered trust company (collectively, the “Warrant Agent”).
PLACEMENT AGENCY AGREEMENT September 28, 2023Placement Agency Agreement • October 3rd, 2023 • Lexaria Bioscience Corp. • Pharmaceutical preparations • New York
PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT LEXARIA BIOSCIENCE CORP.Security Agreement • July 12th, 2024 • Lexaria Bioscience Corp. • Pharmaceutical preparations • New York
THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, xxx or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on February 16, 2029 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Lexaria Bioscience Corp., a Nevada corporation (the “Company”), up to xxxx shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant is issued pursuant to the tail provisions contained in that certain Engagement Agreement, by and between the Company and H.C. Wainwright & Co., LLC, dated as of February 12, 2024.
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • October 16th, 2024 • Lexaria Bioscience Corp. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of October 14, 2024, between Lexaria Bioscience Corp., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
1,828,571 SHARES of Common Stock, 1,828,571 COMMON Warrants OF LEXARIA BIOSCIENCE CORP. UNDERWRITING AGREEMENTUnderwriting Agreement • January 14th, 2021 • Lexaria Bioscience Corp. • Pharmaceutical preparations • New York
The undersigned, Lexaria Bioscience Corp., a company incorporated under the laws of Nevada (collectively with its subsidiaries and affiliates, including, without limitation, all entities disclosed or described in the Registration Statement as being subsidiaries or affiliates of Lexaria Bioscience Corp., the “Company”), hereby confirms its agreement (this “Agreement”) with the several underwriters (such underwriters, including the Representative (as defined below), the “Underwriters” and each an “Underwriter”) named in Schedule I hereto for which H.C. Wainwright & Co., LLC is acting as representative to the several Underwriters (the “Representative” and if there are no Underwriters other than the Representative, references to multiple Underwriters shall be disregarded and the term Representative as used herein shall have the same meaning as Underwriter) on the terms and conditions set forth herein.
PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT LEXARIA BIOSCIENCE CORP.Placement Agent Agreement • February 16th, 2024 • Lexaria Bioscience Corp. • Pharmaceutical preparations • New York
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on February 14, 2029 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Lexaria Bioscience Corp., a Nevada corporation (the “Company”), up to _______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant is issued pursuant to that certain Engagement Agreement, by and between the Company and H.C. Wainwright & Co., LLC, dated as of February 12, 2024.
SHARES OF COMMON STOCK, ________ PREFUNDED WARRANTS, AND _________ COMMON WARRANTS OF LEXARIA BIOSCIENCE CORP. UNDERWRITING AGREEMENTUnderwriting Agreement • January 7th, 2021 • Lexaria Bioscience Corp. • Pharmaceutical preparations • New York
The undersigned, Lexaria Bioscience Corp., a company incorporated under the laws of Nevada (collectively with its subsidiaries and affiliates, including, without limitation, all entities disclosed or described in the Registration Statement as being subsidiaries or affiliates of Lexaria Bioscience Corp., the “Company”), hereby confirms its agreement (this “Agreement”) with the several underwriters (such underwriters, including the Representative (as defined below), the “Underwriters” and each an “Underwriter”) named in Schedule I hereto for which H.C. Wainwright & Co., LLC is acting as representative to the several Underwriters (the “Representative” and if there are no Underwriters other than the Representative, references to multiple Underwriters shall be disregarded and the term Representative as used herein shall have the same meaning as Underwriter) on the terms and conditions set forth herein.
Lexaria Bioscience Corp Common Stock ($0.001 par value per share) Capital on Demand™ Sales AgreementCapital on Demand Sales Agreement • August 22nd, 2024 • Lexaria Bioscience Corp. • Pharmaceutical preparations • New York
Lexaria Bioscience Corp, a Nevada corporation (the “Company”), confirms its agreement (this “Agreement”) with JonesTrading Institutional Services LLC (the “Agent”), as follows:
PREFUNDED COMMON STOCK PURCHASE WARRANT LEXARIA BIOSCIENCE CORP.Prefunded Common Stock Purchase Warrant • January 6th, 2021 • Lexaria Bioscience Corp. • Pharmaceutical preparations • New York
THIS PREFUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) until this Warrant is exercised in full (the “Termination Date”) but not thereafter, to subscribe for and purchase from Lexaria Bioscience Corp., a Nevada corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
UNDERWRITER COMMON STOCK PURCHASE WARRANT LEXARIA BIOSCIENCE CORP.Underwriter Common Stock Purchase Warrant • January 14th, 2021 • Lexaria Bioscience Corp. • Pharmaceutical preparations • New York
THIS UNDERWRITER COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on ______[1] (the “Termination Date”) but not thereafter, to subscribe for and purchase from Lexaria Bioscience Corp., a Nevada corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant is issued pursuant to the Underwriting Agreement.
PURCHASE AGREEMENTPurchase Agreement • April 7th, 2010 • Lexaria Corp. • Metal mining • Nevada
THIS PURCHASE AGREEMENT, dated as of April 1, 2010, is entered into by and among Lexaria Corp., a Nevada corporation with headquarters located at #950-1130 West Pender Street, Vancouver, British Columbia Canada V6E 4A4 (the “Company”), and CAB Financial Services Ltd. of 483 Holbrook Rd, E, Kelowna BC, and any additional purchasers whose signatures appear at the conclusion of this agreement (collectively, the “Purchaser”) as identified in Schedule 1 hereto.
STOCK OPTION AGREEMENT LEXARIA CORP.Stock Option Agreement • April 1st, 2014 • Lexaria Corp. • Metal mining
Lexaria Bioscience Corp. Up to $5,925,000 of Shares of Common Stock Equity Distribution AgreementEquity Distribution Agreement • August 12th, 2022 • Lexaria Bioscience Corp. • Pharmaceutical preparations • New York
Lexaria Bioscience Corp., a Nevada corporation (the “Company”), proposes to issue and sell through Maxim Group LLC (the “Agent”), as exclusive sales agent, shares of common stock, par value $0.001 per share (“Common Stock”), of the Company (the “Shares”) having an aggregate offering price of up to $5,925,000 on terms set forth herein. The Shares consist entirely of authorized but unissued shares of Common Stock to be issued and sold by the Company.
Execution VersionUnderwriting Agreement • October 16th, 2024 • Lexaria Bioscience Corp. • Pharmaceutical preparations • New York
LEXARIA BIOSCIENCE CORP. PRIVATE PLACEMENT SUBSCRIPTION AGREEMENT INSTRUCTIONS TO PURCHASERPrivate Placement Subscription Agreement • September 6th, 2016 • Lexaria Bioscience Corp. • Metal mining • British Columbia
SECURITY AGREEMENTSecurity Agreement • December 2nd, 2011 • Lexaria Corp. • Metal mining • Nevada
SECURITY AGREEMENT, dated as of December 1st, 2011 (this “Agreement”), among Lexaria Corp. (the “Company” or “Debtor”) and the holder or holders of the 12.0% Notes due December 1st, 2012 up to an allowable aggregate limit of US $250,000 (the “Notes”), signatory hereto, their endorsees, transferees and assigns (collectively referred to as, the “Secured Parties”).
LEXARIA CORP. NOTICE OF GRANTStock Option Agreement • June 8th, 2016 • Lexaria Bioscience Corp. • Metal mining • Nevada
This STOCK OPTION AGREEMENT (“Agreement”), dated as of the 3rd day of June, 2016 is made by and between LEXARIA CORP., a Nevada corporation (the “Corporation”), and _____ (the “Optionee,” which term as used herein shall be deemed to include any successor to the Optionee by will or by the laws of descent and distribution, unless the context shall otherwise require).
LOAN AGREEMENTLoan Agreement • December 5th, 2013 • Lexaria Corp. • Metal mining • British Columbia
CONSULTING AGREEMENTConsulting Agreement • July 14th, 2014 • Lexaria Corp. • Metal mining • Ontario
ContractSubscription Agreement • June 19th, 2006 • Lexaria Corp. • Metal mining • Nevada
THESE SECURITIES ARE RESTRICTED SECURITIES AS THAT TERM IS DEFINED IN RULE 144 UNDER THE U.S. SECURITIES ACT OF 1933 (THE "ACT"). AS RESTRICTED SECURITIES, THEY MAY BE RESOLD ONLY IN ACCORDANCE WITH REGULATION S UNDER THE ACT OR PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT OR AN EXEMPTION THEREFROM
LEXARIA CORP. PRIVATE PLACEMENT SUBSCRIPTION AGREEMENT INSTRUCTIONS TO PURCHASERPrivate Placement Subscription Agreement • May 15th, 2015 • Lexaria Corp. • Metal mining • British Columbia
DEBT SETTLEMENT AGREEMENTDebt Settlement Agreement • July 29th, 2009 • Lexaria Corp. • Metal mining
LEXARIA CORP., a company duly incorporated under the laws of the Province of British Columbia and having its registered and records office at Suite 604 – 700 West Pender Street, Vancouver, BC, V6C 1G8 Ph 604-602-1675 FAX 604-685-1602
MANAGEMENT SERVICES AGREEMENTManagement Services Agreement • June 3rd, 2020 • Lexaria Bioscience Corp. • Metal mining • British Columbia
Lexaria Bioscience Corp , a company duly incorporated under the laws of the Province of British Columbia and having its office at 156 Valleyview Rd, Kelowna BC Canada V1X 3M4
FORM OF NOTEPurchase Agreement • April 7th, 2010 • Lexaria Corp. • Metal mining • Nevada
THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES LAWS OF ANY STATE AND MAY NOT BE SOLD OR OFFERED FOR SALE IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES OR AN OPINION OF COUNSEL OR OTHER EVIDENCE ACCEPTABLE TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.
LICENSE AGREEMENTLicense Agreement • January 22nd, 2019 • Lexaria Bioscience Corp. • Metal mining • Virginia
This License Agreement (the “Agreement”), effective as of January 15, 2019 (the “Effective Date”), is entered into by and among Altria Client Services LLC, a Virginia limited liability company with offices located at 6601 West Broad Street, Richmond, Virginia 23220 (“Licensee”), Lexaria Nicotine LLC, a Delaware limited liability company with a principal office and place of business at 100-740 McCurdy Road, Kelowna, BC V1X 2P7, Canada (“Licensor”), and Lexaria Bioscience Corp., a Nevada corporation with a principal office and place of business at 100-740 McCurdy Road, Kelowna, BC V1X 2P7, Canada (“Trademark Licensor”). Licensor and Trademark Licensor may be referred to herein collectively as the “Licensor Parties,” and Licensee, Licensor, and Trademark Licensor may be referred to herein individually as a “Party” or collectively as the “Parties.”
CONSULTING AGREEMENT THIS AGREEMENT is made effective this 2nd day of December, 2010.Consulting Agreement • December 3rd, 2010 • Lexaria Corp. • Metal mining • British Columbia
Lexaria Corp., a body corporate duly incorporated under the laws of the State of Nevada, and having its Registered Office at 950-1130 West Pender, in the City of Vancouver, in the Province/State of British Columbia, V6E 4A4
INTELLECTUAL PROPERTY LICENSE AGREEMENTIntellectual Property License Agreement • November 14th, 2019 • Lexaria Bioscience Corp. • Metal mining • British Columbia
This Intellectual Property License Agreement (this “Agreement”) dated as of July 23, 2019 (the “Effective Date”) is made by and between Lexaria Hemp Corp., a US corporation with offices at #100 – 740 McCurdy Road, Kelowna, British Columbia, V1X 2P7, Canada (the “LICENSOR”), and Hill Street Beverage Company Inc. a Canadian corporation with offices at 480 University Avenue, Suite 1401, Toronto, ON M5G 1V2 (together with its successors and assigns the “LICENSEE”). LICENSOR and LICENSEE are sometimes referred to individually herein as a “Party” and collectively as the “Parties”.
CONSULTING AGREEMENTConsulting Agreement • December 1st, 2008 • Lexaria Corp. • Metal mining • British Columbia
Lexaria Corp., a body corporate duly incorporated under the laws of the State of Nevada, and having its Registered Office at 604 – 700 West Pender, in the City of Vancouver, in the Province/State of British Columbia, V6C 1G8
